Fulgent Genetics, Inc. (FLGT) stock
Close on Nov 17, 2026Market cap $666.15MP/E –Yield –
Earnings
Fulgent Genetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Fulgent Genetics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $90.40M | +7.5% | -$0.48 | -$0.09 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026during market hours | $85.40M | +4.4% | -$1.05 | -$0.58 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 1, 2026before the open | $71.10M | -3.3% | -$0.80 | -$0.36 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 27, 2026before the open | $83.30M | +9.3% | -$0.76 | $0.16 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 7, 2025before the open | $84.07M | +17.3% | -$0.21 | $0.14 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025before the open | $81.80M | +15.2% | -$0.62 | $0.07 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 2, 2025before the open | $73.50M | +14.0% | -$0.37 | $0.04 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025before the open | $76.20M | +8.1% | -$0.19 | $0.04 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024before the open | $71.70M | -15.6% | -$0.48 | $0.31 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 2, 2024before the open | $71.00M | +4.4% | -$0.29 | $0.15 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 3, 2024before the open | $64.50M | -2.6% | $0.45 | $0.01 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | $70.50M | +4.1% | -$4.30 | $0.28 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023before the open | $85.00M | -19.6% | -$0.44 | -$0.39 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | $68.00M | -45.7% | -$0.38 | -$0.08 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 5, 2023before the open | $66.20M | -79.3% | $0.52 | $0.22 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023during market hours | $67.70M | -73.1% | -$0.80 | -$0.48 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022during market hours | $105.70M | -53.6% | $0.06 | $0.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $125.30M | – | $0.37 | $0.78 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022during market hours | $320.30M | – | $4.93 | $5.08 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022during market hours | $251.70M | – | $3.34 | $3.48 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $227.90M | – | $3.93 | $4.05 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 4, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Fulgent Genetics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $330.00M – $340.00M | – | New | Nov 5, 2026 |
| Revenue | FY2026 | $330.00M – $340.00M | $350.00M | Lowered | Jul 30, 2026 |
| Non-GAAP loss per sharenon-GAAP | FY2026 | $1.65 – $1.75 | – | New | Nov 5, 2026 |
| Non-GAAP loss per sharenon-GAAP | FY2026 | -$2.35 – -$2.22 | -$1.59 | Lowered | Jul 30, 2026 |
| Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $630.00M | – | New | Nov 5, 2026 |
| Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $610.00M | $636.00M | Lowered | Jul 30, 2026 |
| Non-GAAP lossnon-GAAP | FY2026 | $46.00M – $50.00M | – | New | Nov 5, 2026 |
| Non-GAAP lossnon-GAAP | FY2026 | -$67.00M – -$63.00M | -$46.00M | Lowered | Jul 30, 2026 |
Guidance vs results
The last range Fulgent Genetics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | EPS (GAAP) | -$1.70 | -$1.96Σ4Q | Below range |
| FY2025 | Non-GAAP income per share | $0.30 | $0.41Σ4Q | Above range |
| FY2025 | Revenue | $325.00M | $322.67MΣ4Q | Below range |
| Q3 FY2023 | Revenue | $65.00M | $85.00M | Above range |
| Q2 FY2023 | Revenue | $62.00M | $68.00M | Above range |
| Q1 FY2023 | Revenue | $56.00M | $66.20M | Above range |
| Q4 FY2022 | Revenue | $60.00M | $67.70M | Above range |
| Q3 FY2022 | Revenue | $105.00M | $105.70M | Above range |
| Q2 FY2022 | Revenue | $125.00M | $125.30M | Above range |
| Q1 FY2022 | Revenue | $245.00M | $320.30M | Above range |
| Q4 FY2021 | Revenue | $189.00M | $251.70M | Above range |
Guidance history
Every forecast Fulgent Genetics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Non-GAAP loss per share | FY2026 | $1.65 – $1.75 | New |
| Nov 5, 2026 | Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $630.00M | New |
| Nov 5, 2026 | Non-GAAP loss | FY2026 | $46.00M – $50.00M | New |
| Nov 5, 2026 | Revenue | FY2026 | $330.00M – $340.00M | New |
| Jul 30, 2026 | Non-GAAP loss per share | FY2026 | -$2.35 – -$2.22 | Lowered |
| Jul 30, 2026 | Non-GAAP loss | FY2026 | -$67.00M – -$63.00M | Lowered |
| Jul 30, 2026 | Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $610.00M | Lowered |
| Jul 30, 2026 | Revenue | FY2026 | $330.00M – $340.00M | Lowered |
| May 1, 2026 | Non-GAAP loss per share | FY2026 | -$1.59 | Lowered |
| May 1, 2026 | Non-GAAP loss | FY2026 | -$46.00M | New |
| May 1, 2026 | Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $636.00M | Lowered |
| May 1, 2026 | Revenue | FY2026 | $350.00M | Reaffirmed |
| Feb 27, 2026 | Non-GAAP loss | FY2026 | -$1.45 | New |
| Feb 27, 2026 | Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2026 | $685.00M | New |
| Feb 27, 2026 | Revenue | FY2026 | $350.00M | New |
| Nov 7, 2025 | Non-GAAP income per share | FY2025 | $0.30 | New |
| Nov 7, 2025 | GAAP loss per share | FY2025 | -$1.70 | New |
| Nov 7, 2025 | Revenue | FY2025 | $325.00M | New |
| Aug 1, 2025 | Non-GAAP loss per share | FY2025 | -$0.35 | Raised |
| Aug 1, 2025 | GAAP loss per share | FY2025 | -$2.10 | Lowered |
| Aug 1, 2025 | Cash, cash equivalents, restricted cash, and investments in marketable securities | FY2025 | $770.00M | Reaffirmed |
| Aug 1, 2025 | Core Revenue | FY2025 | $320.00M | Raised |
| May 2, 2025 | Non-GAAP loss per share | FY2025 | -$0.65 | Reaffirmed |
| May 2, 2025 | GAAP loss per share | FY2025 | -$1.95 | Reaffirmed |
| May 2, 2025 | Cash, cash equivalents, and investments in marketable securities | FY2025 | $770.00M | Lowered |
| May 2, 2025 | Core Revenue | FY2025 | $310.00M | Reaffirmed |
| Feb 28, 2025 | Non-GAAP loss | FY2025 | -$0.65 | New |
| Feb 28, 2025 | GAAP loss | FY2025 | -$1.95 | New |
| Feb 28, 2025 | Cash, cash equivalents, and investments in marketable securities | FY2025 | $780.00M | New |
| Feb 28, 2025 | Core Revenue | FY2025 | $310.00M | New |
| Nov 8, 2024 | Non-GAAP income per share | FY2024 | $0.33 | Raised |
| Nov 8, 2024 | GAAP loss per share | FY2024 | -$1.70 | Raised |
| Nov 8, 2024 | Cash, cash equivalents, and investments in marketable securities | FY2024 | $800.00M | Reaffirmed |
| Nov 8, 2024 | Core Revenue | FY2024 | $280.00M | Reaffirmed |
| Aug 2, 2024 | Non-GAAP loss | FY2024 | -$0.30 | Lowered |
| Aug 2, 2024 | GAAP loss | FY2024 | -$1.95 | Lowered |
| Aug 2, 2024 | Cash, cash equivalents, and investments in marketable securities | FY2024 | $800.00M | Reaffirmed |
| Aug 2, 2024 | Core Revenue | FY2024 | $280.00M | Reaffirmed |
| May 3, 2024 | Non-GAAP loss | FY2024 | $1.05 | Raised |
| May 3, 2024 | GAAP loss | FY2024 | $2.25 | Raised |
| May 3, 2024 | Cash, cash equivalents, and investments in marketable securities | FY2024 | $800.00M | Reaffirmed |
| May 3, 2024 | Core Revenue | FY2024 | $280.00M | Reaffirmed |
| Feb 28, 2024 | Non-GAAP loss per share | FY2024 | -$1.05 | New |
| Feb 28, 2024 | GAAP loss per share | FY2024 | -$2.25 | New |
| Feb 28, 2024 | Cash, cash equivalents, and investments in marketable securities | FY2024 | $800.00M | New |
| Feb 28, 2024 | Core Revenue | FY2024 | $280.00M | New |
| Nov 3, 2023 | Non-GAAP loss | FY2023 | -$0.95 | Reaffirmed |
| Nov 3, 2023 | GAAP loss | FY2023 | -$2.15 | Reaffirmed |
| Nov 3, 2023 | Cash, cash equivalents, and investments in marketable securities | FY2023 | $830.00M | New |
| Nov 3, 2023 | Core Revenue | FY2023 | $260.00M | Reaffirmed |
| Aug 4, 2023 | Non-GAAP loss | FY2023 | -$0.95 | Lowered |
| Aug 4, 2023 | GAAP loss | FY2023 | -$2.15 | Lowered |
| Aug 4, 2023 | Core Revenue | Q3 FY2023 | $65.00M | New |
| Aug 4, 2023 | Core Revenue | FY2023 | $260.00M | Raised |
| May 5, 2023 | Non-GAAP loss | FY2023 | $1.25 | Raised |
| May 5, 2023 | GAAP loss | FY2023 | $2.50 | Raised |
| May 5, 2023 | Core Revenue | Q2 FY2023 | $62.00M | New |
| May 5, 2023 | Core Revenue | FY2023 | $250.00M | Raised |
| Feb 28, 2023 | Non-GAAP loss per share | FY2023 | -$1.25 | New |
| Feb 28, 2023 | GAAP loss per share | FY2023 | -$2.50 | New |
| Feb 28, 2023 | Total Revenue | Q1 FY2023 | $56.00M | New |
| Feb 28, 2023 | Total Revenue | FY2023 | $240.00M | New |
| Nov 7, 2022 | Non-GAAP income | FY2022 | $5.60 | Lowered |
| Nov 7, 2022 | Core Revenue | Q4 FY2022 | $52.00M | New |
| Nov 7, 2022 | Core Revenue | FY2022 | $178.00M | New |
| Nov 7, 2022 | Total Revenue | Q4 FY2022 | $60.00M | New |
| Nov 7, 2022 | Total Revenue | FY2022 | $611.00M | Lowered |
| Aug 4, 2022 | Non-GAAP income | FY2022 | $6.00 | Reaffirmed |
| Aug 4, 2022 | Total Revenue | Q3 FY2022 | $105.00M | New |
| Aug 4, 2022 | Core Revenue | Q3 FY2022 | $54.00M | New |
| Aug 4, 2022 | Total Revenue | FY2022 | $665.00M | New |
| Aug 4, 2022 | Core Revenue | FY2022 | $185.00M | New |
| May 3, 2022 | Non-GAAP income | FY2022 | $6.00 | Lowered |
| May 3, 2022 | Total Revenue | Q2 FY2022 | $125.00M | New |
| May 3, 2022 | Total Revenue | FY2022 | $660.00M | Raised |
| Feb 23, 2022 | Non-GAAP income | FY2022 | $7.00 | New |
| Feb 23, 2022 | GAAP income | FY2022 | $6.00 | New |
| Feb 23, 2022 | Total Revenue | Q1 FY2022 | $245.00M | New |
| Feb 23, 2022 | Total Revenue | FY2022 | $600.00M | New |
| Nov 9, 2021 | Non-GAAP income | FY2021 | $16.00 | New |
| Nov 9, 2021 | GAAP income | FY2021 | $15.50 | New |
| Nov 9, 2021 | Core Revenue | Q4 FY2021 | $32.00M | New |
| Nov 9, 2021 | Core Revenue | FY2021 | $115.00M | New |
| Nov 9, 2021 | Total Revenue | Q4 FY2021 | $189.00M | New |
| Nov 9, 2021 | Total Revenue | FY2021 | $930.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Fulgent Genetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- Update
- Results
- Results
- News
- Results
- Results
- News
See a number that looks wrong?